Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro

被引:40
作者
Gruber, A
Lukasser-Vogl, E
Borg-von Zepelin, M
Dierich, MP
Würzner, R
机构
[1] Univ Innsbruck, Inst Hyg, A-6010 Innsbruck, Austria
[2] Inst AIDS Forsch, Innsbruck, Austria
[3] Univ Gottingen, Inst Hyg, D-3400 Gottingen, Germany
关键词
D O I
10.1086/515231
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Previously, it has been shown that human immunodeficiency virus (HIV)-1 envelope proteins gp160 and gp41 bind to Candida albicans. Whether this interaction affects candidal virulence in vitro was investigated. HIV-1 gp160 or gp120 treatment of C. albicans significantly altered neither growth nor phospholipase activity of the fungus. However, treatment of C. albicans with gp160, but not with gp120, led to an elevation of free and cell-bound aspartate proteinase. In addition, culture supernatants obtained from C. albicans treated with gp160 or gp41, but not with gp120, showed a strong increase in proteinase activity. Finally, C. albicans viable yeast cells treated with gp160 or gp41 and serum were phagocytosed by polymorphonuclear leukocytes to a lesser extent than was C. albicans treated with gp120 and serum or serum alone. These findings suggest that the interaction between HIV-1 gp160 and C. albicans may promote the virulence of C. albicans in HIV-1-positive patients.
引用
收藏
页码:1057 / 1063
页数:7
相关论文
共 46 条
  • [1] INCREASED PHAGOCYTOSIS AND GENERATION OF REACTIVE OXYGEN PRODUCTS BY NEUTROPHILS AND MONOCYTES OF MEN WITH STAGE-1 HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    BANDRES, JC
    TRIAL, J
    MUSHER, DM
    ROSSEN, RD
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (01) : 75 - 83
  • [2] LARGE-SCALE PRODUCTION AND PURIFICATION OF A VACCINIA RECOMBINANT-DERIVED HIV-1 GP160 AND ANALYSIS OF ITS IMMUNOGENICITY
    BARRETT, N
    MITTERER, A
    MUNDT, W
    EIBL, J
    EIBL, M
    GALLO, RC
    MOSS, B
    DORNER, F
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1989, 5 (02) : 159 - 171
  • [3] BERNARD CI, 1994, EUR J CLIN MICROBIOL, V13, P711
  • [4] BORG M, 1990, J MED VET MYCOL, V28, P3
  • [5] ROLE OF CD4+ LYMPHOCYTES IN RESISTANCE TO MUCOSAL CANDIDIASIS
    CANTORNA, MT
    BALISH, E
    [J]. INFECTION AND IMMUNITY, 1991, 59 (07) : 2447 - 2455
  • [6] A T(H)1-]T(H)2 SWITCH IS A CRITICAL STEP IN THE ETIOLOGY OF HIV-INFECTION
    CLERICI, M
    SHEARER, GM
    [J]. IMMUNOLOGY TODAY, 1993, 14 (03): : 107 - 110
  • [7] Candidiasis: The emergence of a novel species, Candida dubliniensis
    Coleman, DC
    Sullivan, DJ
    Bennett, DE
    Moran, GP
    Barry, HJ
    Shanley, DB
    [J]. AIDS, 1997, 11 (05) : 557 - 567
  • [8] PUTATIVE VIRULENCE FACTORS OF CANDIDA-ALBICANS
    CUTLER, JE
    [J]. ANNUAL REVIEW OF MICROBIOLOGY, 1991, 45 : 187 - 218
  • [9] DEBERNARDIS F, 1990, J INFECT DIS, V161, P1276, DOI 10.1093/infdis/161.6.1276
  • [10] Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus
    DeBernardis, F
    Chiani, P
    Ciccozzi, M
    Pellegrini, G
    Ceddia, T
    DOffizzi, G
    Quinti, I
    Sullivan, PA
    Cassone, A
    [J]. INFECTION AND IMMUNITY, 1996, 64 (02) : 466 - 471